AegirBio AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 5.26 million. Net loss was SEK 24.61 million. Basic loss per share from continuing operations was SEK 1.73. For the nine months, sales was SEK 11.87 million. Net loss was SEK 48.89 million. Basic loss per share from continuing operations was SEK 3.43.